Advertisement

Topics

Regeneron profit, revenue beat on Eylea, Dupixent sales

08:40 EST 8 Nov 2017 | Reuters

(Reuters) - Regeneron Pharmaceuticals Inc's third-quarter profit and revenue topped analysts' estimates on Wednesday as demand rose for its flagship eye treatment Eylea and its recently launched eczema drug Dupixent.

Original Article: Regeneron profit, revenue beat on Eylea, Dupixent sales

NEXT ARTICLE

More From BioPortfolio on "Regeneron profit, revenue beat on Eylea, Dupixent sales"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Dermatitis
Dermatitis means an inflammation of the skin. Contact dermatitis is a term used when this inflammation is caused by contact with something in the environment. The changes of dermatitis seen in the skin take the form of eczema; hence it may sometimes be r...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...